FGF-2 increases in groups with colorectal cancer and reaches significance in the group with moderately differentiated adenocarcinoma (G1 versus control p = 0.9; G2 versus control p = 0.014; G3 versus control p = 0.20). The gene discussed is FGF2; the disease is adenocarcinoma.